CD64 CAR T cell therapy for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a type of immunotherapy called CAR T cells that target a protein called CD64 on leukemia cells. It is for adults with AML that has come back or not responded to treatment, including venetoclax.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia (AML) that has returned or not improved after at least one prior treatment including venetoclax.
- Your leukemia cells must have a high level of CD64 protein (70% or more) on their surface.
- You have a plan for a rescue stem cell transplant and are a suitable candidate.
- Your organs are working well enough: kidneys (creatinine clearance at least 30 mL/min), liver (AST/ALT no more than 5 times normal, bilirubin no more than 3 times normal), lungs (minimal breathing difficulty and oxygen level above 92%), and heart (ejection fraction at least 40%).
- You have not had prior CAR T cell therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
Hear when a new Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.